Apellis Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Apellis Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Apellis Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Apellis Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Apellis Pharmaceuticals Inc (Apellis), a subsidiary of Biogen Inc, is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds. The company pipeline products include EMPAVELI (Pegcetacoplan) Injection for the treatment of paroxysmal nocturnal hemoglobinuria, c3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplant-associated thrombotic microangiopathy. Apellis's other pipeline includes SYFOVRE (Intravitreal pegcetacoplan Injection) and APL-APL-3007 + SYFOVRE for treating geographic atrophy. The company is also developing RNA therapies, gene-edited FcRn therapy, gene-edited complement therapies, and oral complement inhibitors for multiple therapeutic areas. It operates in Australia, the US, and Switzerland. Apellis is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
100 Fifth Avenue, Waltham, Massachusetts, 02451
Website
www.apellis.com
Telephone
1 617 9775700
No of Employees
733
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$1.0B
Apellis Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| EMPAVELI (Pegcetacoplan) Injection: |
| Paroxysmal Nocturnal Hemoglobinuria |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, the company secured a capped royalty purchase agreement with Sobi, receiving up to US$300 million for 90% of future royalties outside the US from Aspaveli. |
| 2025 | Regulatory Approval | In January, the company secured approval from the Therapeutic Goods Administration for SYFOVRE (pegcetacoplan) for the treatment of adult patients with geographic atrophy secondary to age-related macular degeneration with an intact fovea and when central vision is threatened by GA lesion growth. |
| 2023 | Regulatory Approval | In October, the company secured an approval from the U.S. Food and Drug Administration for EMPAVELI Injector. |
Competitor Comparison
| Key Parameters | Apellis Pharmaceuticals Inc | Regeneron Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | Astellas Pharma US Inc | Aviceda Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Waltham | Tarrytown | Cambridge | Northbrook | Cambridge |
| State/Province | Massachusetts | New York | Massachusetts | Illinois | Massachusetts |
| No. of Employees | 733 | 15,410 | 2,500 | 3,000 | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gerald Chan | Chairman | Executive Board | 2013 | 74 |
| Cedric Francois | Chief Executive Officer; Director; President | Executive Board | 2009 | 52 |
| Timothy Sullivan | Chief Financial Officer; Treasurer | Senior Management | 2017 | 54 |
| Jim Chopas | Chief Accounting Officer; Controller; Vice President | Senior Management | 2021 | 58 |
| Caroline Baumal | Chief Medical Officer | Senior Management | 2023 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer